Worst of both worlds

Worst of both worlds

Immune Response Corp. shares suffered a 40 percent shellacking last week, which we suppose could be attributed to inconclusive data from the Phase II/III trial of its HIV therapeutic vaccine. Or, equally simply, to the rout of investors who continue to march into the biotech tar pits